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 ABSTRACT 
 
Problem: Asthma requiring daily medication is a major medical condition in nearly 3-
8% of pregnancies. Currently, there are no medications deemed safe by the US Food 
and Drug Administration (FDA) for pregnancy. The effects of many medications are 
still unknown. Purpose: To identify the effects on normal fetal development of 
inhaled corticosteroid use during pregnancy. To identify the role asthma control has on 
fetal development.  Research Questions: Does inhaled corticosteroid use during 
pregnancy cause more congenital anomalies in infants of uncontrolled asthmatics than 
those of controlled asthmatics? Methods: A prospective cohort study will follow 
women from their first prenatal visit through the end of the neonatal period. They will 
be asked to complete surveys regarding asthma symptoms and treatment. Neonates 
will be assessed on days 1 and 28 of postnatal life to assess for any congenital 
malformations. Outcomes:  A literature review was performed and a total of thirteen 
articles were chosen. These articles highlighted the various effects of in utero exposure 
to corticosteroids when taken for maternal asthma.  Benefit:  This prospective cohort 
study will help clinicians better understand the effects of treating asthma during 
pregnancy by giving a better understanding of the potential dangers of uncontrolled 
asthma on fetal development.  
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 Asthma is a common medical condition affecting both children and adults. It is 
classically described as reversible airway disease, because asthmatics’ lung function 
typically improves in response to bronchodilators. Asthmatics typically develop a 
variety of symptoms in response to certain triggers. Treatment involves a stepwise 
approach beginning with short-acting beta agonists as a “rescue” treatment then 
escalating to inhaled corticosteroids for daily symptoms. During pregnancy, 
physiologic changes can affect an asthmatic’s lung function. For example, as the fetus 
develops it may cause diaphragmatic elevation, which leads to a decrease in both 
residual volume (RV) and functional residual capacity (FRC).  
The treatment of asthma in pregnancy is a complex issue centered around 
stabilizing the mother without compromising the health of the fetus. Research studies 
have been divided over the effects of asthma medications on a developing fetus. Many 
articles have found higher rates of preterm labor, low birth weight and congenital 
malformation.  
 
1.1 Pathophysiology of Asthma 
  
By definition, asthma is airway inflammation leading to reversible airway 
obstruction.1 Inflammation typically occurs in response to specific triggers, which vary 
and may include but are not limited to exercise, allergens or air pollution.1 However, 
when exposed to various triggers, asthmatics develop inflammation leading to 
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bronchospasm or bronchoconstriction, which may occur immediately or develop over 
4-6 hours, which is known as a late asthmatic response.1 From a pathophysiologic 
standpoint, bronchoconstriction leads to decreased lung function as measured by 
pulmonary function tests or a peak flow meter.1 Asthmatics typically experience 
decreased forced expiratory volume (FEV1), peak expiratory flow (PEF), and 
FEV1/FVC (forced vital capacity).1 The airway inflammation leads to a smaller airway 
diameter, which results in increased airway resistance.1 These reductions in lung 
function typically improve with administration of a bronchodilator, such as albuterol.2 
Additionally, many asthmatics have normal lung function between exacerbations.2 
Symptomatically, asthmatic patients tend to experience wheezing, chronic cough, 
dyspnea and/or chest tightness in response to various triggers.2 Some asthmatics with 
chronic disease will experience symptoms on a more daily basis, rather than simply 
when exposed to triggers.2  
 
 
1.2 Prevalence of Asthma 
  
Over the past several decades, the incidence of asthma has increased 
significantly and now affects approximately 10% of the population. Additionally, 
asthma tends to affect female adults more than male adults.2 Furthermore, a strong 
genetic predisposition has been identified with asthma, allergies and dermatitis; a triad 
called “atopy.”1 More specifically, the term “atopy” refers to the presence of antigen-
directed IgE antibodies.3 Obesity has also been linked to the development of asthma.1 
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During pregnancy, asthma is one of the most common medical problems encountered, 
occurring in 3-8% of pregnancies.4 
 
1.3 Diagnosis of Asthma 
 
Diagnosis of asthma is made using the medical history, physical exam and lung 
function assessment.2 Historically, patients will present with complaints of episodic 
wheezing, dyspnea and cough.2 Typically, patients may be able to identify specific 
triggers for these symptoms.1 The physical exam may be completely normal at times 
when the patient is asymptomatic.1 Alternatively, the patient may be experiencing 
wheezing if examined during an exacerbation or even a silent chest during a severe 
exacerbation.1 Patients with allergic asthma might exhibit more allergic symptoms 
such as increased swelling and secretions of the nasal mucosa or even nasal polyps. 
Patients with atopy are likely to have eczema or dermatitis.1 Pulmonary function tests 
including spirometry are also utilized in the diagnosis of asthma. When evaluating for 
asthma, spirometry is obtained both before and after the administration of 
bronchodilators.2 An improvement in lung function by 12% or greater strongly 
suggests the presence of asthma.2 
 
1.4       Treatment of Asthma 
 
Treatment of asthma is very complex and depends on the severity and chronicity 
of the disease. When developing a treatment plan for asthmatics, clinicians must take 
into account the types of symptoms, frequency of symptoms and lung function as 
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measured by pulmonary function testing.  This information is used to classify patients 
as either intermittent, mild persistent, moderate persistent or severe persistent. Patients 
are then started on an appropriate management plan based on their categorization.  
Asthma medication can be categorized as either long-term control medications or 
quick relief medications. Long-term control medications include anti-inflammatories, 
long-term bronchodilators, leukotriene modifiers, desensitization, omalizumab, 
vaccination and oral sustained-release beta-2 agonists. Quick relief medications 
include beta adrenergic agonists, anticholinergics, corticosteroids, antimicrobials and 
phosphodiesterase inhibitors.2 
Some patients, specifically those in the “intermittent” category, may require only a 
beta agonist to be used as a “rescue inhaler” when symptomatic whereas other patients 
with “persistent” asthma may require daily medication to control symptoms interfering 
with daily activities. Patients with mild persistent asthma typically begin with inhaled 
corticosteroids and may be titrated up using a “stepwise” approach, which can later 
include combination therapy with inhaled corticosteroids and long acting beta 
agonists. During exacerbations, oral corticosteroids may be utilized.5 
 
1.5        Treatment of Asthma in Pregnancy 
 
As mentioned above, asthma can be treated in a variety of ways but when treated 
appropriately using the stepwise approach, treatment has been shown to reduce 
symptoms and improve quality of life.5 However, pregnancy complicates the matter as 
it can both affect the underlying asthma and be affected by asthma. Treating a 
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pregnant asthmatic requires clinicians to take into account the needs of the mother 
while maintaining safety of the fetus, leaving the clinician faced with a balancing act.4 
Finding the balance between adequately treating the mother without harmful effects on 
the fetus is extremely complex. Additionally, uncontrolled asthma in the mother may 
lead to harmful effects on the fetus including hypoxia.5 
As with any medication, inhaled corticosteroids may have potential maternal side 
effects.2 Local side effects including cough, hoarseness and oral thrush are much more 
common than systemic side effects, as seen with oral corticosteroids.2 However, at 
high doses easy bruising, bone density changes and adrenal suppression may occur.2 
Complicating the issue even further is the US Food and Drug Administration 
(FDA) categories of asthma medication.  The FDA classifies all medication into five 
categories based on the presumed safety of the medication on the fetus based on 
animal studies. Category “A” is any drug which has been proven to be safe in pregnant 
women. However, no asthma medication belongs to category “A.” In fact, most 
asthma medications are category “C” meaning that risk has neither been proven or 
disproven, leaving clinicians with a difficult choice to make between the health of 
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CHAPTER II 
REVIEW OF THE LITERATURE 
2.1 Method 
 
This thesis began with research using the search engine Google Scholar, which 
resulted in many scholarly works. The initial search term used was “asthma in 
pregnancy.” As expected, this returned a search of tens of thousands of articles. The 
search was further narrowed by searching the terms “asthma treatment in pregnancy.” 
Furthermore, some articles used were articles listed as “related articles” to ones found 
through Google Scholar. Lastly, to broaden the scope and not be limited by the use of 
only one search engine, the same search terms “asthma treatment in pregnancy” were 




The search term “asthma treatment in pregnancy” through the use of Google 
Scholar yielded approximately 180,000 results in 0.8 seconds. The same search using 
the PubMed database yielded 1809 articles. These results were then narrowed down 
using a variety of inclusion and exclusion criteria. Firstly, the inclusion criteria 
included only studies that took place within the past twenty years with special 
attention being placed on articles within the past five years. While some might argue 
that research from nearly twenty years ago holds little value today, with this particular 
issue this seems not to be the case as the pendulum has swung back and forth 
regarding treatment of asthma in pregnancy. Additionally, specific medications may 
have changed slightly during that time, but overall asthma management has stayed 
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relatively the same with an emphasis on inhaled corticosteroids for mild and moderate 
persistent asthma, and beta agonists and oral corticosteroids for acute exacerbations. 
Another important inclusion criterion was that articles had to follow patients over a 
period of time, rather than just during a single exacerbation. This was important as 
asthma tends to wax and wane, particularly during pregnancy. Therefore, treatment of 
a single exacerbation may not provide adequate data on the severity of the mother’s 
asthma nor on the effect on the fetus. Additional criteria included articles written in 
English, which did not require translation services, as information may be skewed in 
translation. 
Literature reviews which did not include any original research were initially 
excluded because these articles do not provide any additional data. However, after 
more research it became apparent that literature reviews contribute a wealth of 
information and a better understanding of the topic, and the exclusion criteria were 
subsequently revised. While initially the search was limited to articles with a large 
sample size, the search became difficult and the criteria limited articles with good data 
and important conclusions, despite a small sample size. Therefore, articles were not 
excluded based on sample size. However, the smaller sample size has been taken into 
account when looking at the validity of various articles. An additional exclusion 
criterion was that the articles had to focus exclusively on asthma, rather than asthma 
and other comorbidities including allergic rhinitis. Articles were not excluded based 
on geographic location as asthma affects all populations and has similar treatment 
approaches globally.  
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2.3 Discussion 
 
After accounting for the aforementioned inclusion and exclusion criteria 11 
articles were selected, which shed light on the treatment of asthma in pregnancy. This 
section of the paper discusses each article and how it contributes to the current 
understanding of both the effects of asthma and pregnancy, and the role of treatment in 
asthma in pregnancy. 
The first study by Cydulka et al corroborates data obtained during two 
prospective cohort studies and examines how pregnant asthmatics presented 
differently than a non-pregnant cohort during an acute exacerbation requiring an 
emergency room visit. In the emergency department, historical data was collected 
including demographics, chronic asthma history and information related to the current 
exacerbation.  Objective data included the PEFR (Peak Expiratory Flow Rate), which 
was utilized to categorize the exacerbation as mild, moderate or severe. This work 
interestingly points out that, while both pregnant and non-pregnant asthmatics had 
similar presentations, their treatment plans vastly varied leaving the pregnant 
asthmatics with worse outcomes.6 While each woman was equally likely to receive 
nebulized albuterol initially, non-pregnant women were much more likely to receive 
oral corticosteroids than their counterparts with 66% of non-pregnant women 
receiving oral corticosteroids as compared to 44% of pregnant asthmatics (p=0.002).6 
Additionally, Cydulka et al compared outcomes two weeks after discharge and found 
that pregnant asthmatics were more likely to still be symptomatic at that time 
(p=0.09).6 Of note, this study is limited by its small population with only 51 
asthmatics participating, compared to 500 non-pregnant women.6 Despite being 
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written in 1999, this articles provides useful data that sheds light on the management 
of pregnant asthmatics in the emergency department. Furthermore, no data was 
obtained to suggest that this management has drastically changed since the article was 
written in 1999.   
While Cydulka et al provide key background information regarding maternal 
presentation and outcomes of emergency department visits for asthma exacerbations, 
the remainder of the articles focus more on the specific treatments and their effects on 
the mother, the fetus or both. Some of these articles focused on specific treatments and 
looked for specific side effects, while others were much broader and examined 
outcomes in general. One article that focuses on a very specific outcome is by 
Tegethoff et al, which is a prospective cohort study examining the use of inhaled 
corticosteroids in pregnancy and more specifically whether this treatment leads to an 
increased risk of childhood diabetes. Any pregnant asthmatic with a singleton birth 
was eligible to join the study and was followed from early pregnancy through 
childhood. Tegethoff et al did find an increased incidence of metabolic and endocrine 
disorders in children born to asthmatic mothers treated with inhaled corticosteroids 
with 43.94% versus 29.2%, p=0.012.7 However, they did not find a significant 
difference in intrapartum complications or birth defects.7 Separating this article from 
many others was the exceptionally large population, with an n = 65,085. Some of the 
pitfalls of this article include that the source of the information regarding the 
children’s health was from the mothers rather than physicians, and this study did not 
account for the amount and type of exposure to inhaled corticosteroids.  
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A similar article that also examined the effect of inhaled corticosteroids on the 
fetus was an article entitled Fetal Glucocorticoid-Regulated Pathways Are Not 
Affected by Inhaled Corticosteroid Use for Asthma During Pregnancy by Hodyl et al, 
which is a prospective study that examined the effects of inhaled corticosteroids on 
pregnancy and fetal development by measuring maternal plasma levels of four 
hormones involved in the glucocorticoid pathway including cortisol, estriol, 
osteocalcin and corticotropin releasing hormone. Unlike the previous Tegethoff et al 
study, Hodyl et al accounted for the amount of inhaled corticosteroid exposure by 
measuring the dose and usage of the inhaler. The Hodyl study did not find any 
significant difference in plasma levels of the estriol in pregnant versus non-pregnant 
women.8 From this finding, the authors concluded that inhaled corticosteroid use does 
not affect fetal glucocorticoid pathways.8 Interestingly, mothers carrying female 
fetuses were more likely to experience hypothalamus-pituitary-axis suppression than 
both their non-pregnant counterparts and pregnant mothers carrying male fetuses.8 
One major limitation to this study is that women were asked whether or not they used 
inhaled corticosteroids during pregnancy, but some women may have remembered 
incorrectly or confused albuterol for an inhaled steroid.  
Unlike the previous two articles, which focused specifically on inhaled 
corticosteroids and the effects on glucocorticoids, many articles focused more broadly 
on the effects of asthma on congenital malformations. Interestingly, among the various 
articles different results were obtained. The Blais et al study is a follow-up to an 
earlier study by the same researchers, who previously identified increased congenital 
birth defects in fetuses born to mothers with asthma. However, this retrospective 
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cohort study comprising 36,587 pregnant women found that only severe exacerbations 
had a statistically higher rate of birth defects with 19.1% of babies born to mothers 
with severe asthma exacerbations suffering from congenital malformations.9 
Furthermore, if this exacerbation occurred during the first trimester, the researchers 
found a significant odds ratio of 1.64 with a 95% confidence interval of 1.02 to 2.64.9 
The criteria included by Blais et al, but was not limited to delivering between January 
1998 and March 2009, which allowed the sample size to be much larger than many 
similar studies. Additionally, inclusion criteria controlled for other potential causes of 
birth defects including gestation age and maternal age. However, acceptable 
gestational age was between 20 and 45 weeks, which is not very limiting and includes 
fetuses who are not yet considered viable. Furthermore, the maternal age range was 
between 15 and 45, which is inconsistent given the significantly increased risk of birth 
defects with increasing maternal age. This study also classified the types of congenital 
malformation based on their severity, but while severe asthma exacerbations were 
associated with increased risk for congenital malformations, there was no correlation 
between mild, moderate and severe asthma with mild, moderate and severe congenital 
malformations.  
Similarly to the Blais et al study, a study by Murphy et al entitled The Risk of 
Congenital Malformations, Perinatal Mortality and Neonatal Hospitalisation Among 
Pregnant Women with Asthma: A Systematic Review and Meta-Analysis also found 
higher rates of congenital malformations in babies born to asthmatic mothers. Murphy 
et al is a meta-analysis of four prospective cohort studies and eight retrospective 
cohort studies, which sought to identify a relationship between maternal asthma and 
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congenital malformations and overall neonatal outcomes. Women were classified 
based on medication use, exacerbations requiring medical intervention and asthma 
severity. Data was collected using a standardized form that was reviewed by a second 
interviewer to ensure accuracy. Murphy et al found a significantly higher risk of 
congenital defects in asthmatics than in their counterparts with a relative risk of 1.11, 
95% CI 1.02-1.21, p<0.1. Additionally, there was an increased odds ratio of 1.18 (CI 
1.03-1.35).10 
Interestingly, all pregnant asthmatics had the same increased risk for 
congenital defects regardless of which medications they received or how many 
exacerbations they suffered. The various studies differed in the types of congenital 
malformations that they found to occur most commonly. For example, Kallen et al 
found cardiac defects to occur more commonly, but Blais et al found nervous system 
defects to occur more commonly, though all studies found there to be an increased risk 
of congenital malformations in babies born to mothers with asthma.10 The researchers 
also studied the relationship between asthma and stillbirths and did not find a 
significantly increased risk for stillbirth in asthmatic mothers with a RR = 1.06 CI 
0.90-1.25, p>0.1.10 However, the researchers did find an increased risk of neonatal 
death (RR = 1.49 95% CI 1.11-2.00) and increased perinatal mortality (RR = 1.25% 
95% CI 1.05-1.50). 10 This article utilized observational data from thousands of 
pregnant women creating a large sample size. However, the observational nature of 
the study makes the data less reliable as it was self-reported and therefore could be 
inaccurate. Overall, this study builds from the previous Blais study and was very 
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informative. The Murphy et al article provides clinicians with a better understanding 
of what specific risks pregnant asthmatics may face. 
Risk of Congenital Anomalies After Exposure to Asthma Medication in the 
First Trimester of Pregnancy – a Cohort Linkage Study by Garne et al also focuses on 
the potential congenital anomalies that may result secondary to asthma medication.  
Garne et al is a meta-analysis of data obtained during three different cohort studies, 
which collectively examined 519,242 fetuses and infants in Norway, Wales and 
Denmark between the years of 2000 and 2010. Garne et al included all live births, 
stillbirths and spontaneous abortions occurring after 20 weeks. Additionally, they 
included any fetus who was electively terminated due to fetal anomaly, regardless of 
gestational age.  Of these 519,242 the researchers focused on the 19,513 fetuses whose 
mothers were treated with at least one asthma medication beginning 91 days before 
pregnancy through 91 days after pregnancy. Statistical analysis then included odds 
ratios, which were combined using Mantel-Haenszel methods. Furthermore, 99% 
confidence intervals were combined using Cornfield approximation. Lastly, individual 
odds ratios (ORs) were calculated for each medication separately, providing individual 
data specific to that medication rather than based on exposure in general.  Garne et al 
found that 650 of the 19,513 fetuses exposed to any medication had a major congenital 
malformation with an adjusted OR of 1.21 (99% CI 1.09-1.34).11  Additionally, 512 
fetuses exposed to inhaled beta-2 agonists, 492 fetuses exposed to short-acting beta-2 
agonists, 42 fetuses exposed to long-acting beta-2 agonists, 202 fetuses exposed to 
inhaled corticosteroids, 202 fetuses exposed to combination treatments and 47 fetuses 
exposed to systemic corticosteroids were all noted to have congenital anomalies with a 
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99% confidence interval.11 Of significance, the article points out that the only anomaly 
noted to be significant at the 1% level was the increased risk of anal atresia or stenosis 
in fetuses exposed to inhaled steroids with an OR = 3.40, 99% CI 1.15-10.04.11 
However, this anomaly only occurred in 6 of 202 fetuses exposed to inhaled 
corticosteroids, illustrating that, despite being statistically significant, the incidence 
rate is still quite low. In fact, Garne et al conclude that most of these congenital 
defects occurred in anywhere from 1 in 1000 to 1 in 10,000 births depending on which 
medications the fetus is exposed to. This article provides a comprehensive breakdown 
of specific congenital anomalies and which medications they are associated with, 
providing clinicians with excellent data regarding risk of exposure. However, the data 
is somewhat confusing as many of these medications were used in conjunction with 
other medications, making it difficult to attribute the teratogenic effects to just one 
medication. 
A study that focused on a more specific outcome was Van Zutphen et al which 
was a multi-center, population-based case control study which sought to determine if 
there is a correlation between asthma medication and 37 different congenital heart 
defects (CHD). The study spanned 10 states within the continental United States and 
studied infants born with congenital heart defects between October 1, 1997 and 
December 31, 2007. Infants with known genetic syndromes or defects were then 
excluded from the study. Additionally, stillbirths with confirmed CHD on autopsy 
were included in the “case” group. For all other infants included in the “case” 
category, diagnosis was made by echocardiogram, catheterization or surgery. The 
control group was a randomly selected set of infants born in the same locations with 
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birth certificates or hospital records. The mothers of both case and control group 
patients were then contacted within two years of their expected due date for a 
structured telephone interview, which collected demographic information as well as 
information regarding maternal health. Specifically, mothers were asked about past 
medical history, their medication use, as well as potential behavioral and 
environmental influences in the perinatal period.  Mothers were asked to recall the 
specific prescription and over the counter medications taken from three months prior 
to pregnancy throughout the pregnancy itself. Additionally, they were asked to recall 
the timing of when they took each specific medication. Women were then categorized 
based on which type of medications they used, bronchodilators, anti-inflammatories or 
a combination of the two. They further categorized the women based on when the 
exposure occurred. Women who were exposed from one month prior to conception 
through the end of the first trimester were categorized as being exposed during “the 
critical period of cardiac development.” However, those who had been exposed prior 
to one month before conception or after the first trimester were considered to have 
been exposed after cardiac development. Exclusion criteria included multiple 
gestations and diabetic mothers. An odds ratio was then calculated which attempted to 
take into account confounding factors such as body mass index (BMI) and tobacco 
use. Of the 37 congenital heart defects studied, only three were found to have 
statistically significant increased risks in asthmatic mothers.12 Specifically, mothers 
who used only bronchodilators, 85% of whom used albuterol, were found to have an 
increased risk of delivering an infant with anomalous pulmonary venous return with 
an OR = 2.3 (95% CI = 1.1, 4.8).12 Conversely, mothers who only used anti-
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inflammatory medications, (46.1% used fluticasone and 15.6% used prednisone) were 
found to be at increased risk of delivering infants with transposition of the great 
arteries, OR = 2.0 (95% CI = 1.0, 4.3).12 Lastly, mothers who used both categories of 
medications, bronchodilators and anti-inflammatory medications, were found to be at 
increased risk of coarctation of the aorta, OR = 2.1 (95% CI 0.9, 5.0).12  However, 
none of the other congenital heart defects were found in statistically significant higher 
rates among asthmatic mothers.12  
While this study clearly shows an increased risk of only three of 37 studied 
congenital heart defects, it is not specific to inhaled corticosteroids. In fact, all 
medications that are considered “anti-inflammatory” were studied together. However, 
this group included both inhaled and oral corticosteroids. Additionally, this study 
interviewed mothers up to 24 months after their expected delivery date and then asked 
them to recall medications taken. Therefore, it is unclear how accurately these mothers 
may have remembered. Another limitation of this study is that it did not take into 
account how well controlled the asthma was during pregnancy.   
Another study by Garne et al utilized a population-based case-control study in 
Europe to determine if there is an increased risk of congenital malformations in 
neonates born to mothers being treated for asthma during the first trimester. Garne 
used data collected through a European database entitled EUROCAT, which is a 
national database of birth defects which includes information on live births, fetal 
demise after 20 weeks gestational age and any “termination of pregnancy for fetal 
anomaly (TOPFAs).” The researchers used information obtained from thirteen 
different registries in twelve European countries to identify a population of 76,249 
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congenital malformations between the years 1995 and 2010 in the selected countries. 
Anyone with a congenital malformation that previous literature deemed to be 
associated with asthma was placed in the “case” group. Those anomalies that were not 
previously found to be associated with asthma were then divided into two groups 
based on whether or not chromosomal abnormalities were present. Both the 
chromosomal and nonchromosomal group made up the “control” group. Data was then 
collected from various medical providers and prescription databases regarding the 
exposure of the fetus to any asthma medication during the first trimester. Those who 
were exposed were then further categorized into three groups based on type of 
exposure, beta-2 agonists, inhaled corticosteroids or “all asthma medication.” The case 
and control groups were then compared for each congenital malformation including 
spina bifida, cleft lip, cleft palate only, cleft lip with cleft palate, major cardiac, severe 
congenital heart disease, tetralogy of fallot, esophageal atresia, anorectal atresia, 
gastroschisis, omphalacele and hydrospadias. Interestingly, this study did not find 
increased risk for any of the birth defects in fetuses exposed to inhaled corticosteroids 
during the first trimester.13 However, increased rates of cleft palate and gastroschisis 
were found to be associated with beta-2 agonist exposure with OR = 1.63 (95% CI 
1.05-2.52) and OR = 1.89 (95% CI 1.12-3.20) respectively.13 Additionally, the cases 
who were categorized “all asthma medication” were also found to have higher rates of 
anal atresia with OR = 1.64 (95% CI 1.18 -3.44).13  
While this article seems to contradict the previous two articles in that it did not 
find significant differences following exposure to inhaled corticosteroids, its 
methodology varied significantly. First of all, this study only measured exposure as 
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being exposure during the first trimester, whereas the previous two articles looked at 
exposure from 1 month prior to conception through the end of pregnancy. 
Additionally, this study looked at inhaled corticosteroid use separately rather than 
looking at all corticosteroid use together, regardless of route of administration.  
 
Similarly to the above article, a study by Skuladottir et al also did not find 
statistically significant differences between asthmatics and non-asthmatics. They 
chose a study design using data from the National Birth Defects Prevention Study 
(NBDPS), which was a “population-based, multi-center case-control” study that 
collected data on all births between October 1997 and December 2009, which 
occurred at any of the chosen study centers across ten different states. The study was 
comprised of data from all living infants and stillbirths, with diagnosis of orafacial 
clefts, such as cleft lip with palate (CLP) or cleft palate only (CPO), being made either 
clinically, surgically or on autopsy. Any deliveries resulting in either of these defects 
were then classified as “case” infants, with the “control” group consisting of those 
infants born without orofacial defects. Any “case” infant, who was believed to have an 
alternative cause of the defect was subsequently excluded from the study. Data was 
then collected in the same fashion as in the above article examining CHD, in that 
mothers were interviewed by telephone anywhere from six weeks to two years after 
estimated date of delivery (EDD). During these interviews they were asked to answer 
questions regarding preexisting medical conditions, any medications taken beginning 
three months prior to conception through delivery --- and the duration of such 
medications, and any other medical complications arising during pregnancy. 
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Researchers then used logistic regression models to compare rates of orofacial defects 
in infants born to mothers with exposure to corticosteroids as compared to those who 
were not exposed to corticosteroids. The data collected was then further examined 
according to when in pregnancy the exposure occurred and the route of administration 
to see if there were any specific correlations with orofacial defects. A total of 8924 
mothers were enrolled with 66.4% (5922) delivering neonates without orofacial 
defects, classified as the “control” group. Of the 3002 infants with malformations, 
52.5% (1577) had both cleft lip and cleft palate (CLP), with the remainder of the 
mothers enrolled (795) delivering infants with cleft palate only (CPO).14 Of the control 
group, 2.4% of mothers were noted to have corticosteroid exposure from one month 
before conception through the end of the first trimester. During that same time period, 
2.3% of infants with CLP had mothers who reported corticosteroid exposure, OR = 1.0 
(95% CI 0.7-1.4), and 1.7% of infants with CPO had mothers who reported 
corticosteroid exposure, OR = 0.7 (95% CI 0.4-1.2).14 Interestingly, researchers did 
not find any statistically significant differences based on mode of delivery or the 
specific compound of medication. Based on these results, Skuladottir concluded that 
there was no statistically significant difference between mothers exposed to 
corticosteroids and those without exposure.14 The researchers also point out that this 
data directly contradicts earlier research performed using the NBDPS data collected 
from 1997-2002, which stated that exposure to corticosteroids was associated with an 
increased risk of CLP, OR = 2.7 (95% CI 1.1 – 6.7).14 However, Skuladottir also 
points out that the earlier data was specific to prednisone, not all corticosteroids, and 
was only administered orally and therefore had systemic absorption, whereas the more 
  20 
recent data incorporated all modes of administration and compounds of 
corticosteroids. Similarly to the article above, which also used data collected by the 
NBDPS, this study design has a major flaw as it relies on self-reported information, 
which dates back as far as two years prior. Additionally, this study is very broad as it 
includes all modalities of corticosteroids used for a variety of medical conditions and 
is not specific to asthma.  
Unlike the previous studies, which compared congenital malformations in 
pregnant women with asthma as compared to women without asthma, the Eltonsy 
article Risk of Congenital Malformations for Asthmatic Pregnant Women Using a 
Long-Acting β2-Agonist and Inhaled Corticosteroid Combination Versus Higher-Dose 
Inhaled Corticosteroid Monotherapy is a cohort study, which sought to compare the 
risk of serious congenital malformations seen in women with asthma after exposure to 
long-acting B2- agonist (LABA) and inhaled corticosteroids and those on 
monotherapy of inhaled corticosteroids at higher doses during the first trimester. The 
question at hand is whether the combination of LABA and ICS is safe during 
pregnancy. A population-based retrospective cohort study design was used. Patients 
were selected from the Quebec Asthma and Pregnancy database, from a period of 
1990-2010. A total of 6632 patients were involved in the study, which was a 
sufficiently large sample size for this purpose. The instance of major malformation 
was recorded at birth during the first two years of life in the child. The sample 
population was separated into users of LABA in addition to ICS and users of LABA 
plus medium dose ICS combinations. What the results showed were that prevalence of 
major malformations was similar in both sub-categories with a prevalence of 6.9% 
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among women treated with LABA plus low-dose ICS as compared to a prevalence of 
7.2% among women treated with LABA plus either medium-dose or high-dose ICS.15 
When evaluating the risk of ICS alone, some prior studies have stated that there is no 
increase of risk of congenital malformations with ICS use, while others have found 
that there was a 63% increase of malformations when using high doses of ICS 
compared with low-to-moderate doses of ICS during the first trimester.15  
Another study that looked more broadly at the effect of asthma on pregnancy 
was by Grzeskowiak et al entitled Patterns, Predictors and Outcomes of Asthma 
Control and Exacerbations During Pregnancy: A Prospective Cohort Study. This 
study sought to determine the relationship between asthma exacerbations and perinatal 
outcomes. Through a non-interventional prospective cohort study, 189 women were 
recruited between May 2009 and May 2012. During that time, the women were 
assessed by a midwife at 12, 20, 28 and 36 weeks gestation; the midwife collected 
various data including demographic, maternal smoking, socioeconomic, asthma 
therapy, asthma control, asthma triggers, comorbid medical conditions, asthma 
hospitalizations and oral contraceptive use. An exacerbation was considered moderate 
or severe if a woman needed medical intervention including hospitalization, 
emergency room visit, emergency doctor appointment or oral corticosteroids. 
Interestingly, Grzeskowiak found a direct relationship between weeks of gestation and 
asthma exacerbations.16 While the study did not find maternal smoking, age or weight 
to be predictive factors for asthma exacerbations, they did find those factors could be 
protective factors. Specifically, younger women, non-smokers and women with lower 
BMIs were all less likely to have exacerbations or uncontrolled asthma. Women who 
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were found to have uncontrolled asthma at two or more prenatal visits were more 
likely to have daughters who were small for their gestational age (SGA), occurring in 
33.3% as opposed to 9.5% in their non-asthmatic or well controlled counterparts with 
p = 0.018.16 However, uncontrolled asthma did not put women at increased risk for 
preterm birth, which occurred in 11.1% of births as opposed to 9.5% of births with a p 
=1.000.16 However, women who were found to have uncontrolled asthma at two or 
more prenatal visits who were carrying male fetuses, were more likely to experience 
preterm birth, occurring in 25% of births compared to 11.8% (p = 0.201), but had an 
equal risk for delivering a baby determined to be SGA, which occurred in 8.3% of 
births as compared to 11.8% (p =1.000).16 
Similarly to the Grzeskowiak study, the Dembrowski article “Asthma During 
Pregnancy” also broadly examines the risks and outcomes of maternal asthma during 
pregnancy. This study was a multicenter, prospective observational cohort study, 
which took place over 4 years and examined the role of moderate and severe asthma 
on the perinatal period, specifically focusing on pre-term delivery.  This article sought 
to prove that moderate and severe asthmatics were more likely to deliver before 32 
weeks, as compared to non-asthmatics.  Dombrowski further stratified asthmatics by 
severity with categories of mild and moderate-severe based on FEV1, symptoms and 
medication use. Furthermore, they sought to enroll 900 patients into each of these 
categories, with another 900 in the control group. There were several exclusion criteria 
to ensure the validity of the study including known multiple gestation, intrauterine 
fetal demise, significant congenital defects, other comorbid pulmonary illnesses, lack 
of ultrasound prior to 26 weeks or enrollment in an asthma control study.  
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Statistical analysis was performed by the Biostatics Center of George 
Washington University using SAS 8.2 Statistical Software, which utilized the Kruskal-
Wallis, Chi-Squared and logistic regression studies, which were reported as an odds 
ratio. A confidence interval of 95% was applied with p < .05 being considered 
statistically significant. Logistic regression took into account a variety of variables, 
which could affect the results including previous obstetrics history, tobacco use, race, 
insurance and level of education. When comparing gestational diabetes, they also 
accounted for additional measures such as BMI and steroid medications.  
Interestingly, Dombrowski found that there were no significant differences 
between mild asthmatics and moderate-severe asthmatics in terms of pre-term delivery 
with a prevalence of 3% among moderate and severe asthmatics, 3.4% among mild 
asthmatics and 3.3% among the control group.17 However, subsequent post-hoc testing 
demonstrated asthmatic mothers were more likely to develop gestational diabetes. 
There was also an increased risk of pre-term labor, before 37 weeks, and an increased 
need for cesarean sections among asthmatics, but only among those stratified into the 
moderate-severe category. As to be expected, women were also more likely to 
experience wheezing during labor with increasing severity of asthma. Additionally, 
neonates born to asthmatic mothers fared the same as neonates born to the control 
group. One result that seems to defy logic was the finding that neonatal sepsis was 
highest amongst babies born to mothers with mild asthma, when compared to the 
control group and the moderate-severe group.  
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2.4 Implications For Further Research 
 
Upon review of the literature, it appears that much of the data that currently 
exists regarding treatment of asthma looks at the potential congenital malformations 
secondary to corticosteroid use. However, little research seems to exist which 
compares inhaled corticosteroid use in controlled and uncontrolled asthma. It is 
important to determine whether it is truly the corticosteroids or the level of control 
which dictates neonatal outcomes and risk of birth defects. Understanding this will 
help clinicians better understand how to treat asthma in pregnancy and will contribute 
to the current debate between the health of the mother and the health of the baby.  
 
 







3.1.1 Project Overview 
 
This thesis project explores some of the many issues that providers must take 
into account when treating pregnant asthmatics. Treating asthma in pregnancy is an 
extremely complex issue as there are at least two patients that must be cared for, as is 
the case with all pregnancies. However, asthma is already a complex disease with a 
variety of treatments. As demonstrated in the above literature review, it is well 
understood that corticosteroid use during pregnancy is associated with a range of 
congenital malformations, preterm labor and low birth weights. However, it is not well 
understood if there is a difference between controlled asthmatics and uncontrolled 
asthmatics. By using a prospective cohort study this thesis explores the effect of 
corticosteroids on fetal development and the neonatal period, and more specifically if 
this effect differs in controlled versus uncontrolled asthmatics. Corticosteroids, 
specifically inhaled corticosteroids, are at the cornerstone of asthma treatment. 
Therefore, it is imperative that one understands what role they play in fetal 
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3.1.2 Research Questions 
 
While there are many questions that could be asked about this topic, this thesis 
focuses on one specific research question. Is there a difference in congenital 
malformations among controlled versus uncontrolled asthmatics being treated with 
inhaled corticosteroids? Asthma is treated in a stepwise approach beginning with 
inhaled corticosteroids, therefore understanding their impact is most important as they 
are most widely prescribed. A better understanding of this questions will help 
researchers determine if corticosteroids should be administered during pregnancy, and 
if so, what outcomes mothers can expect. 
  
3.1.3 Specific Aims 
  
AIM 1:  To provide a better understanding of the effects of inhaled corticosteroids on 
congenital malformations among controlled and uncontrolled asthmatics.  
Specifically, whether or not congenital malformations occur in equal rates 
when inhaled corticosteroids are prescribed for maternal asthma regardless of the 
status of the mother’s asthma. 
AIM 2: To help clinicians better understand the effects of prescribing inhaled 




 Null Hypothesis: There is no difference in congenital malformations among 
neonates born to asthmatic mothers treated with inhaled corticosteroids in 
controlled versus uncontrolled asthma. 
Alternative Hypothesis: There will be increased rates of congenital 
malformations among neonates born to mothers with uncontrolled asthma 
treated with inhaled corticosteroids. 
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Inhaled corticosteroids are at the forefront of asthma maintenance in mild and 
moderate asthmatics. While combination therapy with inhaled corticosteroids and long 
acting beta agonists (LABA) are used for severe asthmatics. Most asthmatics requiring 
daily medication take inhaled corticosteroids.  
 
  
3.2.2 Project Significance 
 
Much literature exists regarding the possible harmful effects of exposing a 
fetus to both oral and inhaled corticosteroids. However, much of this literature poses 
conflicting information. Additionally, these studies often examine the congenital 
malformations that may occur secondary to corticosteroid exposure. However, little 
data exists which directly compares inhaled corticosteroid use in controlled versus 
uncontrolled asthmatics. Understanding this is crucial as many asthmatics require 
treatment with inhaled corticosteroids and those women are warned about the potential 
harmful side effects, which includes but is not limited to congenital malformations. 
However, it is unclear if all women can expect the same side effects. Perhaps, 
controlled asthmatics have decreased risk of congenital malformations as compared 
with uncontrolled asthmatics despite comparable oral corticosteroid use.  
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Understanding this relationship is crucial both for prescribers and for patients 
to understand. If the alternative hypothesis proves to be true, it might act as proof that 
providers should prescribe inhaled corticosteroids more liberally. In fact, if the 
congenital malformations seem to be associated with uncontrolled asthma rather than 
with the inhaled corticosteroids, perhaps the management of pregnant asthmatics 
should be changed to reflect this data. At the present time, asthmatics who are rarely 
symptomatic are not prescribed inhaled corticosteroids. However, if research proves 
that congenital malformations are more likely to occur in uncontrolled asthmatics, 
regardless of daily inhaled corticosteroid use, it may be wise to treat all pregnant 
asthmatics with inhaled corticosteroids to prevent their asthma from becoming 
uncontrolled and thereby reduce the risk of congenital malformations.  
 
3.3 Preliminary Studies 
 
 Not Applicable 
 
 





This paper is proposing a prospective cohort study, which will follow pregnant 
asthmatics receiving inhaled corticosteroids through the neonatal period to assess for 
congenital malformations. This study will be prospective as not all congenital 
malformations may be well documented. Additionally, some asthmatics may not 
accurately recall how well controlled their asthma was during pregnancy. 
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This prospective cohort study will enroll women at their first prenatal visit. All 
participating obstetricians will administer a questionnaire to all patients at their first 
prenatal visit asking if they have asthma, if they take medication, and if they are 
willing to participate in a study. Women will be then be selected based on the 
following inclusion and exclusion criteria. After they are selected they will be asked to 
fill out a daily survey online asking them what medication they took for their asthma 
that day and what symptoms they experienced. The questionnaire will also highlight if 
they needed to use a rescue inhaler such as albuterol, or if they sought medical 
attention for their asthma.  Lastly, the questionnaire will ask about possible 
environmental toxins that could be worsening asthma. They will continue to fill out 
this questionnaire daily for the remainder of the pregnancy. They will then be asked to 
fill out two more questionnaires, one on day one of life for their baby and one on day 
28 of life. These last two questionnaires will focus on any complications with the 
baby, specifically any birth defects or malformations. After mothers have delivered, 
the data regarding symptoms and medication usage will be used to categorize mothers 
as controlled or uncontrolled asthmatics.  
Controlled asthma will be defined as asthma that requires albuterol no more 
than two times weekly, no more than two nocturnal awakenings due to asthma 
monthly and no need for oral steroids.   Once asthmatics have been categorized as 
uncontrolled versus uncontrolled, researchers will extract data from the second two 
questionnaires to determine the number of congenital malformations occurring in each 
group.  
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3.4.2 Methods  
 
The subjects for this study will include any asthmatic between the ages of 20 
and 39 attending their first prenatal visit, who meet the following criteria. Women will 
be selected for the study if they are attending a first prenatal visit no more than 10 
weeks from their last known menstrual period, have an official diagnosis of asthma 
and have taken or are taking inhaled corticosteroids for their asthma. Women will be 
excluded from the study if they have a history of congenital malformations with a 
previous pregnancy, have a known genetic mutation that puts their babies at risk for 
congenital malformations and are taking any medications with known teratogenic 
effects. Additionally, women will be excluded if they engage in any alcohol, tobacco 
or illicit drug use during pregnancy.  
This study will use controlled and uncontrolled asthma as the independent 
variables with congenital malformations being the dependent variables.  
 
  
3.4.3 Statistical Analysis 
 
This research will utilize a chi-squared test of independence to compare two 
sets of nominal data (incidence of congenital malformation in controlled versus 
uncontrolled asthma). 
 
The statistical analysis includes: 
1. p < 0.05 
2. Desired power = 0.95 
3. Minimum sample size = 220 
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3.4.4 Limitations 
  
As with any research project, this study has several limitations. Firstly, it is 
rather difficult to encourage participants to fill out daily questionnaires. However, 
understanding daily symptoms is crucial to understanding asthma control. Similarly, 
the status of one’s asthma is constantly changing as someone may be controlled for the 
majority of pregnancy, but then develop an upper respiratory infection at 38 weeks 
gestational age, causing an exacerbation and shifting that participant from the 
“controlled” to the “uncontrolled” group. Furthermore, asthma is typically treated in a 
stepwise fashion; therefore, anyone whose asthma is classified as “uncontrolled” 
should be treated with additional medication to help control their asthma. However, 
the additional medication may range from oral corticosteroids to addition of a long 
acting beta agonist. Therefore, if there is a difference between “controlled” and 
“uncontrolled” asthmatics, it may be difficult to assess whether this difference is due 
to asthma control as opposed to whatever additional medication is being given to treat 
the poorly controlled asthmatics. Another confounding variable that needs to be 
accounted for is environmental factors that could be contributing to both poor asthma 
control as well as congenital malformations. For example, if someone is living in an 
apartment with mold, which will worsen asthma, but may also lead to fetal anomalies. 
 
 
 3.4.5 Timeline  
 
The study will follow patients for approximately 9 months, but will enroll 
patients for a total of three years to obtain a meaningful sample size. Approval will be 
obtained by the Institutional Review Board (IRB) prior to enrolling patients. Patients 
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will be recruited at their initial prenatal visit, which is approximately 8 weeks after 
their last menstrual period. Patients will continue to be followed throughout pregnancy 
with routine prenatal visits a recommended by the American College of Obstetrics and 
Gynecology. Their babies will then be followed from birth until the end of the 
neonatal period at 28 days.  
  




 Asthma is one of the leading medical complications occurring in pregnancy, 
which has become increasingly more widespread over time. Understanding how to 
treat asthma during pregnancy is a hotly debated topic, for which the pendulum has 
swung back and forth over time. As with any complication of pregnancy, at least two 
lives must be considered at all times. Understanding how to treat the mother without 
harming the fetus is often tricky and can be the source of much debate. Additionally, 
with so many classes of medications currently in existence to treat asthma it is often to 
difficult to know which ones are best for the fetus.  
 
Asthma is currently treated with a stepwise approach with most asthmatics 
receiving inhaled corticosteroids for daily symptoms. However, per FDA regulations, 
no inhaled corticosteroid is currently deemed safe for pregnancy, considered to be 
category “A.” In fact, most asthma medications are categorized as a “C.” As 
evidenced by the literature above, corticosteroids have been shown to be associated 
with poorer outcomes in pregnancy including preterm labor, low birth weights and 
increased congenital malformations. Despite the evidence in this literature, there 
continues to be a debate between obstetricians, pulmonologists and pediatricians 
regarding the treatment of asthma in pregnancy. One piece of information that is 
currently missing, which may help guide clinicians in future practice, is whether these 
outcomes associated with corticosteroid use are affected by the level of control of the 
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asthma. By using a prospective cohort study this paper hopes to determine if there is a 
correlation between asthma control and congenital malformations in the setting of 
inhaled corticosteroid use. By understanding this relationship, we will have a better 
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